The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies

Vaccine

Volumn 14, Issue 5, 1996, Pages 359-368

  Ibsen, Per H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Detoxification; Epitopes; Monoclonal antibodies; Pertussis toxin; Solid and soluble phase ELISA

Indexed keywords

EPITOPE; FORMALDEHYDE; HYDROGEN PEROXIDE; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PERTUSSIS; PRIORITY JOURNAL; QUALITY CONTROL; VACCINATION;

EID: 0029881645     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00230-X     Document Type: Article

References (36)

1. Rappuoli, R., Podda, A., Pizza, M., Covacci, A., Bartoloni, A., de Magistris, M.T. and Nencioni, L. Progress towards the development of new vaccines against whooping cough. Vaccine 1992, 10, 1027-1032
2. Fine, P.E.M. and Clarkson, J.A. Reflections on the efficacy of pertussis vaccines. Rev. Infect Dis. 1987, 9, 866-883
3. Barkin, R.M. and Pichichero, M.E. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics 1979, 63, 256-260
4. Cody, C.L., Baraff, L.J., Cherry, J.D., Marcy, S.M. and Manclark, C.R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68, 650-660
5. Halperin, S.A., Barreto, L., Friesen, B. and Meekison, W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch. Ped. Adol. Med. 1994, 148, 495-502
6. Kimura, M., Kuno-Sakai, H., Sato, Y. et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Am. J. Dis. Child. 1991, 145, 734-741
7. Miller, E., Ashworth, L.A.E., Robinson, A., Waight, P.A. and Irons, L.I. Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet 1991, 337, 70-73
8. Podda, A., De Luca, E.C., Contu, B. et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. J. Ped. 1994, 124, 921-926
9. Ruuskanen, O., Noel, A., Putto-Laurila, A. et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991, 9, 117-121
10. Sato, Y., Kimura, M. and Fukumi, H. Development of a component pertussis vaccine in Japan. Lancet 1984, i, 122-126
11. Siber, G.R., Thakrar, N., Yancey, B.A. et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 1991, 9, 735-740
12. Vanura, H., Just, M., Ambrosch, F. et al. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 μg of FHA and either 25 or 8 μg of PT with response to whole-cell pertussis DTP vaccine. Vaccine 1994, 12, 210-214
13. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden -protective efficacy and adverse events. Lancet 1988, i, 955-960
14. Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Mollby, R. and Miller, E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990, 8, 457-461
15. Tamura, M., Nogimori, K., Murai, S. et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982, 21, 5516-5522
16. Tamura, M., Nogimori, K., Yajima, M., Ase, K. and Ui, M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J. Biol. Chem. 1983, 258, 6756-6761
17. Chong, P., Zobrist, G., Sia, C., Loosmore, S. and Klein, M. Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides. Infect. Immun. 1992, 60, 4640-4647
18. Munoz, J.J., Arai, H., Bergman, R.K. and Sadowski, P.L. Biological activities of crystalline pertussigen from Bordetella pertussis. Infect. Immun. 1981, 33, 820-826
19. Fish, F., Cowell, J.L. and Manclark, C.R. Proliferative response of immune mouse T-lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis. Infect. Immun. 1984, 44, 1-6
20. Sekura, R.D., Zhang, Y., Roberson, R. et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J. Ped. 1988, 113, 806-813
21. Quentin-Millet, M.J., Arminjon, F., Danve, B., Cadoz, M. and Armand, J. Acellular pertussis vaccines: evaluation of reversion in a nude mouse model. J. Biol. Stand. 1988, 16, 99-108
22. Storsaeter, J., Olin, P., Renemar, B. et al. Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Ped. Infect Dis. J. 1988, 7, 637-645
23. Loosmore, S.M., Zealey, G.R., Boux, H.A. et al. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect. Immun. 1990, 58, 3653-3662
24. Nencioni, L., Pizza, M., Bugnoli, M. et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 1990, 58, 1308-1315
25. Pizza, M., Covacci, A., Bartoloni, A. et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989, 246, 497-500
26. Nencioni, L., Volpini, G., Peppoloni, S., Bugnoli, M., DeMagistris, T., Marsili, I. and Rappuoli, R. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect. Immun. 1991, 59, 625-630
27. Capiau, C., Petre, J., Van Damme, J., Puype, M. and Vanderkerckhove, J. Protein-chemical analysis of pertussis toxin reveals homology between the subunits S2 and S3, between S1 and the A chains of enterotoxins of Vibrio cholerae and Escherichia coli and identifies S2 as the haptoglobin-binding subunit. FEBS Lett. 1986, 204, 336-340
28. Schou, C., Au-Jensen, M. and Heron, I. The interaction between pertussis toxin and 10 monoclonal antibodies. Acta Pathol. Microbiol. Immunol. Scand. Sect. C 1987, 95, 177-187
29. Ibsen, P.H., Holm, A., Petersen, J.W., Olsen, C.E. and Heron, I. Identification of B-cell epitopes on the S4 subunit of pertussis toxin. Infect. Immun. 1993, 61, 2408-2418
30. Petersen, J.W., Holm, A., Ibsen, P.H., Hasløv, K., Capiau, C. and Heron, I. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin. Infect. Immun. 1992, 60, 3962-3970
31. Root, D.D. and Wang, K. Kinetic silver staining and quantification of proteins adsorbed to microtiter plates. Anal. Biochem. 1993, 209, 354-359
32. Gillenius, P., Jäätmaa, E., Askelöf, P., Granström, M. and Tiru, M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biol. Stand. 1985, 13, 61-66
33. Ferguson, M., Wood, D.J. and Minor, P.D. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 1993, 74, 685-690
34. Lang, A.B., Ganss, M.T, and Cryz, S.J. Jr Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect. Immun. 1989, 57, 2660-2665
35. Nicosia, A., Bartoloni, A., Perugini, M. and Rappuoli, R. Expression and immunological properties of the five subunits of pertussis toxin. Infect. Immun. 1987, 55, 963-967
36. Sato, H. and Sato, Y. Structural relationship between the S1 and S4 subunits of pertussis toxin. FEMS Microbiol. Lett. 1994, 115, 63-70